Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
9.94
+0.03 (0.30%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Zenas BioPharma Revenue
In the year 2024, Zenas BioPharma had annual revenue of $5.00M, down -90.00%. Zenas BioPharma had revenue of $5.00M in the quarter ending December 31, 2024.
Revenue (ttm)
$5.00M
Revenue Growth
-90.00%
P/S Ratio
26.35
Revenue / Employee
$38,462
Employees
130
Market Cap
417.16M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
Dec 31, 2023 | 50.00M | - | - |
Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionZBIO News
- 2 days ago - Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses - GlobeNewsWire
- 3 days ago - Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses - GlobeNewsWire
- 7 days ago - Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. (ZBIO) - GlobeNewsWire
- 7 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst - Seeking Alpha
- 17 days ago - Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer - GlobeNewsWire
- 5 weeks ago - Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress - Benzinga
- 5 weeks ago - Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer - GlobeNewsWire